Skip to content

Telos Biotech

7 viewers · 30d

Total raised

$725K

1 filing since 2025 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $725K
ROUNDS
1
INVESTORS
4
FOUNDED
N/A
HQ
Dallas, TX
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
7

AI overview

Updated

Telos Biotech is a biotechnology startup that develops technologies to enhance the manufacturing of cell therapies. The company, launched by Cambrian Bio in 2022, focuses on addressing telomere shortening during cell expansion to improve the function, longevity, and robustness of therapeutic cells used to treat cancer and age-related diseases.

What sets it apart

The company's key differentiator is its selective telomere lengthening approach, which specifically targets and extends only the shortest telomeres. This method is designed to be safer and more effective than traditional methods, resulting in more robust and durable engineered cells.

Funding history

1 round
Equity+1Dec 1, 2025
Form D
+$725K$725K total

Latest SEC filings

via EDGAR · CIK 0001815708
Form D · Dec 1, 2025View on EDGAR

Products

1 tracked

Telovance™

Biotech Platform Technology

Telovance™ is a proprietary protein complex delivered during the ex-vivo cell expansion phase of manufacturing. It works by rapidly and safely lengthening the shortest telomeres within the therapeutic cells, without the risks associated with constitutive telomerase expression.

  • Selectively targets and lengthens critically short telomeres
  • Improves cellular lifespan, function, and therapeutic outcomes
  • Designed for seamless integration into multi-step cell engineering workflows
  • Enhances the fitness of various cell types, including CAR-T cells